PTC THERAPEUTICS, INC.
PTCT · XNASCIK 1070081fmd_02XK4XT42H9GWNB0MR5F72T7Z0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 60 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 83 | 194 | 265 | 307 | 381 | 539 | 699 | 938 | 807 | 1,731 |
| Cost of revenue | 0 | 5 | 13 | 12 | – | – | – | – | – | – |
| Gross profit | 83 | 190 | 252 | 295 | – | – | – | – | – | – |
| Research and development | 118 | 117 | 172 | 257 | 478 | 541 | 651 | 667 | 534 | 455 |
| Selling, general and administrative | 97 | 121 | 154 | 203 | 245 | 286 | 326 | 333 | 301 | 347 |
| Total operating expenses | 215 | 259 | 380 | 548 | 813 | 913 | 1,146 | 1,377 | 1,109 | 864 |
| Operating income | (132) | (64) | (116) | (241) | (432) | (374) | (447) | (440) | (303) | 867 |
| Other non-operating income (expense) | (1) | (1) | 0 | 14 | 85 | (58) | (49) | 10 | 7 | (18) |
| Income before taxes | (142) | (78) | (128) | (240) | (403) | (518) | (587) | (696) | (363) | 697 |
| Income tax expense | 1 | 1 | (0) | 12 | 35 | 6 | (28) | (70) | 0 | 14 |
| Net income from continuing operations | (142) | (79) | (128) | (252) | (438) | (524) | (559) | (627) | (363) | 683 |
| Net income | (142) | (79) | (128) | (252) | (438) | (524) | (559) | (627) | (363) | 683 |
| Net income to common shareholders | – | – | (128) | (252) | (438) | (524) | (559) | (627) | (363) | 683 |